Magnus Financial Group LLC Boosts Holdings in Pfizer Inc. (NYSE:PFE)

Magnus Financial Group LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.3% in the first quarter, HoldingsChannel.com reports. The firm owned 42,734 shares of the biopharmaceutical company’s stock after buying an additional 548 shares during the period. Magnus Financial Group LLC’s holdings in Pfizer were worth $1,083,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. D Orazio & Associates Inc. boosted its holdings in shares of Pfizer by 5.5% in the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 391 shares during the period. Lipe & Dalton lifted its position in shares of Pfizer by 17.7% in the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 400 shares in the last quarter. Beam Wealth Advisors Inc. lifted its position in shares of Pfizer by 1.5% in the fourth quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company’s stock worth $728,000 after purchasing an additional 401 shares in the last quarter. Providence Capital Advisors LLC lifted its position in shares of Pfizer by 0.4% in the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company’s stock worth $3,034,000 after purchasing an additional 409 shares in the last quarter. Finally, Donaldson Capital Management LLC lifted its position in shares of Pfizer by 1.2% in the fourth quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company’s stock worth $947,000 after purchasing an additional 410 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE opened at $23.36 on Friday. The firm has a market cap of $132.81 billion, a PE ratio of 16.57, a PEG ratio of 0.64 and a beta of 0.57. The firm’s 50 day moving average price is $22.95 and its 200 day moving average price is $25.00. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter last year, the company posted $0.82 earnings per share. The company’s revenue for the quarter was down 7.8% compared to the same quarter last year. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.36%. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Analyst Ratings Changes

PFE has been the subject of a number of research analyst reports. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target for the company. UBS Group increased their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.